Autoantibodies Against Human Recombinant Erythropoietin in Myelodysplatic Syndrome Patients
NCT01548495 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2012-03-09
Summary
The purpose of this study is to verify the presents of autoantibodies in serums of MDS serum patients who had an inadequate response or did not respond to Recombinant human erythropoietin (rHuEPO) treatment.
Conditions
- Myelodysplatic Syndrome
Sponsors & Collaborators
-
yair levy
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-05-31
- Primary Completion
- 2013-05-31
- Completion
- 2013-09-30
Countries
- Israel
Study Locations
More Related Trials
-
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
NCT03682536 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid
NCT00437450 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of Sustained Erythropoietin Therapy
NCT00542568 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)
NCT02428686 ·Status: COMPLETED ·Phase: PHASE2
-
Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function
NCT00418119 ·Status: UNKNOWN ·Phase: PHASE4
-
The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic
NCT00002303 ·Status: COMPLETED ·Phase: NA
-
Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.
NCT01624038 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)
NCT00443339 ·Status: UNKNOWN ·Phase: PHASE2
-
Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome
NCT01546337 ·Status: TERMINATED
-
A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07075484 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
NCT02612558 ·Status: COMPLETED ·Phase: PHASE2
-
Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers
NCT04954989 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
NCT02999984 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia
NCT00954486 ·Status: WITHDRAWN ·Phase: NA
-
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
NCT01949805 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins
NCT00211029 ·Status: COMPLETED
-
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
NCT00144495 ·Status: COMPLETED ·Phase: PHASE3
-
Prognostic Value of Serum Erythropoietin Level,Ferritin Level and Fibrinogen in Adult Low Risk MDS
NCT04573686 ·Status: UNKNOWN
-
Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma
NCT04910594 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
NCT05485948 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia
NCT00002042 ·Status: COMPLETED ·Phase: NA
-
A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.
NCT00605345 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
NCT01868477 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant
NCT00576602 ·Status: TERMINATED ·Phase: PHASE4
-
Anti-CD38 Antibody Treating Evans Syndrome
NCT06014775 ·Status: RECRUITING ·Phase: PHASE2